ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 408,64
0,00%
Dow Jones
42 297,12
0,86%
DAX
20 132,85
-0,44%
Brent Oil
79,80
-0,60%
Bitcoin
94 972,98
0,49%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Relmada Therapeutics Inc (RLMD) Cours

Relmada Therapeutics Inc

Relmada Therapeutics Inc (RLMD)

NASDAQ
0,404
-0,0084
(-2,04%)
Fermé 14 Janvier 10:00PM
Retardé de 15 minutes
0,4061
0,0021
(0,52%)
Après les heures de négociation: 11:59PM
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
0,4061
Prix Achat
0,4061
Prix Vente
0,42
Volume échangé
532 366
0,3752 Fourchette du Jour 0,4443
0,3416 Plage de 52 semaines 7,2225
Cap du marché
12,254M
Clôture Veille
0,4124
Ouverture
0,4181
Dernière Transaction
15
@
0.4199
Dernière heure de transaction
Volume financier
US$ 217 722
VWAP
0,40897
Volume moyen (3 m)
1 067 550
Actions en circulation
30 174 202
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,12
Bénéfice par action (BPA)
-3,27
Chiffre d'affairess
-
Bénéfice net
-98,79M

À propos de Relmada Therapeutics Inc

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmet... Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.relmada.com
Siège social
Reno, Nevada, USA
Fondé
-
Relmada Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker RLMD. Le dernier cours de clôture d'Relmada Therapeutics était de US$0,41. Au cours de la dernière année, les actions de Relmada Therapeutics ont été négociées dans une fourchette de prix de US$ 0,3416 à US$ 7,2225.

Relmada Therapeutics compte actuellement 30 174 202 actions en circulation. La capitalisation boursière d'Relmada Therapeutics est de US$12,44 million. Relmada Therapeutics a un ratio cours/bénéfice (ratio PE) de -0.12.

RLMD Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

06 Janvier 2025
Edgar (US Regulatory)

Form 8-K - Current report

09 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

04 Décembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Novembre 2024
Edgar (US Regulatory)

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Sept. 16, 2024 NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...

17 Septembre 2024
PR Newswire (US)

Form EFFECT - Notice of Effectiveness

13 Septembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

11 Septembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

11 Septembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

11 Septembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.0639-13.59574468090.470.490.38948522580.44691043CS
40.051414.49111925570.35470.53280.341611132510.43138777CS
12-3.2039-88.75069252083.613.980.341610675500.68270607CS
26-3.6639-90.02211302214.074.370.34165720631.09494222CS
52-2.7039-86.94212218653.117.22250.34163673781.85161239CS
156-19.5239-97.96236828919.9338.680.34163887497.84426664CS
260-38.2739-98.950103412638.68540.341628550512.72705121CS

RLMD - Frequently Asked Questions (FAQ)

What is the current Relmada Therapeutics share price?
The current share price of Relmada Therapeutics is US$ 0,4061
How many Relmada Therapeutics shares are in issue?
Relmada Therapeutics has 30 174 202 shares in issue
What is the market cap of Relmada Therapeutics?
The market capitalisation of Relmada Therapeutics is USD 12,44M
What is the 1 year trading range for Relmada Therapeutics share price?
Relmada Therapeutics has traded in the range of US$ 0,3416 to US$ 7,2225 during the past year
What is the PE ratio of Relmada Therapeutics?
The price to earnings ratio of Relmada Therapeutics is -0,12
What is the reporting currency for Relmada Therapeutics?
Relmada Therapeutics reports financial results in USD
What is the latest annual profit for Relmada Therapeutics?
The latest annual profit of Relmada Therapeutics is USD -98,79M
What is the registered address of Relmada Therapeutics?
The registered address for Relmada Therapeutics is 50 WEST LIBERTY STREET SUITE 880, RENO, NEVADA, 89501
What is the Relmada Therapeutics website address?
The website address for Relmada Therapeutics is www.relmada.com
Which industry sector does Relmada Therapeutics operate in?
Relmada Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PHIOPhio Pharmaceuticals Corporation
US$ 6,50
(284,62%)
281,98M
SLRXSalarius Pharmaceuticals Inc
US$ 3,65
(133,23%)
120,26M
VRMEVerifyMe Inc
US$ 4,1575
(63,04%)
57,6M
ATPCAgape ATP Corporation
US$ 1,9645
(55,91%)
84,16M
AVGRAvinger Inc
US$ 0,8248
(46,47%)
9,78M
EHGOEshallgo Inc
US$ 1,2408
(-62,06%)
6,74M
CMTLComtech Telecommunications Corporation
US$ 2,3491
(-43,12%)
4,37M
SVMHSRIVARU Holding Ltd
US$ 0,0352
(-43,04%)
184,27M
LAESSEALSQ Corporation
US$ 3,35
(-41,54%)
89,92M
NMHINatures Miracle Holding Inc
US$ 1,12
(-38,80%)
735,08k
GCTKGlucoTrack Inc
US$ 0,1493
(27,61%)
685,02M
PHIOPhio Pharmaceuticals Corporation
US$ 6,50
(284,62%)
281,98M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0627
(-28,83%)
232,25M
NVDANVIDIA Corporation
US$ 133,23
(-1,97%)
204,68M
RGTIRigetti Computing Inc
US$ 6,0344
(-32,43%)
192,21M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
RLMD
Relmada Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés